MXPA05003293A - Derivados de 2-oxohidropiridina n-sustituidos. - Google Patents

Derivados de 2-oxohidropiridina n-sustituidos.

Info

Publication number
MXPA05003293A
MXPA05003293A MXPA05003293A MXPA05003293A MXPA05003293A MX PA05003293 A MXPA05003293 A MX PA05003293A MX PA05003293 A MXPA05003293 A MX PA05003293A MX PA05003293 A MXPA05003293 A MX PA05003293A MX PA05003293 A MXPA05003293 A MX PA05003293A
Authority
MX
Mexico
Prior art keywords
alkyl
alkylcarbamoyl
alkylamino
lower alkyl
hydroxy
Prior art date
Application number
MXPA05003293A
Other languages
English (en)
Inventor
Nagai Keita
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MXPA05003293A publication Critical patent/MXPA05003293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto de la formula (I): en donde Ar1 y Ar2 son independientemente arilo o heteroarilo, cualquiera de los cuales esta opcionalmente sustituido por un sustituyente que se selecciona del grupo que consiste de ciano, halogeno, nitro, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, cicloalquilo inferior, ciclo(alquil inferior) °alquilo inferior, alquenilo inferior, alquilamino inferior, dialquilamino inferior, alcanoilamino inferior, alquisulfonilamino inferior, arilsulfonilamino, hidroxi, alcoxi inferior, haloalcoxi inferior, ariloxi, heteroariloxi, alquiltio inferior, carboxilo, formilo, alcanoilo inferior, alcoxicarbonilo inferior, carbamoilo, alquilcarbamoilo inferior, dialquilcarbamoilo inferior, alquilsulfonilo inferior, arilsulfonilo, arilo y heteroarilo; R1 y R2 son independientemente alquilo inferior, cicloalquilo inferior, ciclo (alquil inferior) °alquilo inferior o alcoxi inferior, cualquiera de los cuales esta opcionalmente sustituido por un sustituyente que se selecciona del grupo que consiste de halogeno, alquilamino inferior, dialquilamino inferior, alcanoilamino inferior, hidroxi, alcoxi inferior, formilo, alcoxicarbanilo inferior, alquil carbamoilo inferior y dialquilcarbamoilo inferior; R1, R4 y R5 son independientemente hidrogeno, ciano, halogeno, hidroxi o alquilo inferior, alcoxi inferior o alquiltio inferior, los ultimos tres grupos estan opcionalmente sustituidos por un sustituyente que se selecciona del grupo que consiste de halogeno, alquilamino inferior, dialquilamino inferior, alcanoilamino inferior, hidroxi, alcoxi inferior, formilo, alcoxicarbonilo inferior, alquilcarbamoilo inferior y dialquilcarbamoilo inferio), o una sal o ester del mismo que es util como un agente antagonista del receptor de neuropeptido y tambien es util como un agente para el tratamiento de bulimia, obesidad o diabetes.
MXPA05003293A 2002-09-30 2003-09-25 Derivados de 2-oxohidropiridina n-sustituidos. MXPA05003293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002287015 2002-09-30
JP2002353202 2002-12-05
PCT/JP2003/012290 WO2004031175A2 (en) 2002-09-30 2003-09-25 N-substituted-2-oxodihydropyridine derivatives as npy antagonists

Publications (1)

Publication Number Publication Date
MXPA05003293A true MXPA05003293A (es) 2005-10-18

Family

ID=32072466

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003293A MXPA05003293A (es) 2002-09-30 2003-09-25 Derivados de 2-oxohidropiridina n-sustituidos.

Country Status (17)

Country Link
US (2) US6869966B2 (es)
EP (1) EP1546133B1 (es)
KR (1) KR20050059217A (es)
CN (1) CN100528864C (es)
AR (1) AR041374A1 (es)
AT (1) ATE461191T1 (es)
AU (1) AU2003273522B2 (es)
BR (1) BR0314965A (es)
CA (2) CA2726754C (es)
DE (1) DE60331751D1 (es)
MX (1) MXPA05003293A (es)
NO (1) NO20052106L (es)
PE (1) PE20050087A1 (es)
PL (1) PL376475A1 (es)
RU (1) RU2005113310A (es)
TW (1) TW200407138A (es)
WO (1) WO2004031175A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4887139B2 (ja) * 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602004010206T2 (de) * 2003-08-13 2008-10-09 Takeda Pharmaceutical Co. Ltd. Dipeptidyl Peptidase Inhibitoren.
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2559302C (en) * 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
PT1942898E (pt) * 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
WO2007033266A2 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
JP5122462B2 (ja) * 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007115967A1 (en) * 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Crystalline isopropanol solvate of glucokinase activator
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2741644C (en) 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN106659721B (zh) * 2014-04-09 2021-01-01 基因泰克公司 用于制备药物的方法
CN109369538B (zh) * 2018-11-30 2021-01-22 华南农业大学 一种n-二氟甲基唑类硫(硒)脲衍生物及其制备方法
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH234887A (de) * 1942-12-11 1944-10-31 Ag J R Geigy Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid.
CZ403592A3 (en) * 1992-02-20 1993-12-15 Hoechst Ag Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use
AU757290B2 (en) * 1998-03-25 2003-02-13 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
ES2236178T3 (es) * 2000-02-22 2005-07-16 Banyu Pharmaceutical Co., Ltd. Nuevos compuestos de imidazolina.

Also Published As

Publication number Publication date
AU2003273522B2 (en) 2009-05-21
DE60331751D1 (de) 2010-04-29
CN1684954A (zh) 2005-10-19
CA2726754C (en) 2013-04-02
CA2497237C (en) 2011-03-29
AR041374A1 (es) 2005-05-11
KR20050059217A (ko) 2005-06-17
TW200407138A (en) 2004-05-16
AU2003273522A1 (en) 2004-04-23
WO2004031175A3 (en) 2005-02-24
US20040072874A1 (en) 2004-04-15
BR0314965A (pt) 2005-08-02
CA2497237A1 (en) 2004-04-15
CN100528864C (zh) 2009-08-19
US7138525B2 (en) 2006-11-21
US6869966B2 (en) 2005-03-22
ATE461191T1 (de) 2010-04-15
EP1546133B1 (en) 2010-03-17
RU2005113310A (ru) 2005-11-10
CA2726754A1 (en) 2004-04-15
EP1546133A2 (en) 2005-06-29
WO2004031175A2 (en) 2004-04-15
PE20050087A1 (es) 2005-02-22
US20050009879A1 (en) 2005-01-13
PL376475A1 (en) 2005-12-27
NO20052106L (no) 2005-04-29

Similar Documents

Publication Publication Date Title
MXPA05003293A (es) Derivados de 2-oxohidropiridina n-sustituidos.
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
SG140591A1 (en) Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MXPA05008878A (es) Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
WO2005009975A3 (en) Benzimidazole derivatives as mek inhibitors
GB0130341D0 (en) Compounds
CY1109624T1 (el) Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
SG163547A1 (en) 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
CY1109087T1 (el) Ενωση ιμιδαζο[4,5-c]πυριδινης και μεθοδος αντι-ιικης θεραπειας
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
WO2008079972A3 (en) 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
WO2006110173A3 (en) Novel compounds
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.